(Q51636999)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27424159%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

title

A first-in-human phase I study to evaluate the MEK1/2 inhibitor, cobimetinib, administered daily in patients with advanced solid tumors (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27424159%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

13

Branimir I Sikic

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27424159%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

author name string

Lee S Rosen

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27424159%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

Patricia LoRusso

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27424159%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

Wen Wee Ma

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27424159%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

Jonathan W Goldman

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27424159%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

Amy Weise

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27424159%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

A Dimitrios Colevas

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27424159%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

Salim Yazji

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27424159%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

Angela Shen

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27424159%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

Stuart Johnston

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27424159%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

Hsin-Ju Hsieh

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27424159%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

Iris T Chan

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27424159%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

Alex Adjei

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27424159%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

publication date

16 July 2016

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27424159%20AND%20SRC:MED&resulttype=core&format=json

Investigational New Drugs

18 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27424159%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

volume

34

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27424159%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27424159%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

page(s)

604-613

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27424159%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s10637-016-0374-3

18 March 2020

exact match

0 references

cites work

Mutations of the BRAF gene in human cancer, by Davies et al. (Nature 2002; 417: 949-54).

1 reference

https://api.crossref.org/works/10.1007%2FS10637-016-0374-3

CI-1040 (PD184352), a targeted signal transduction inhibitor of MEK (MAPKK)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-016-0374-3

RAS oncogenes: the first 30 years.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-016-0374-3

Ras oncogenes: split personalities

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-016-0374-3

Intermittent administration of MEK inhibitor GDC-0973 plus PI3K inhibitor GDC-0941 triggers robust apoptosis and tumor growth inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-016-0374-3

Advances in targeting signal transduction pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-016-0374-3

MEK and the inhibitors: from bench to bedside

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-016-0374-3

The RAF proteins take centre stage

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-016-0374-3

BRAF mutation predicts sensitivity to MEK inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-016-0374-3

Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-016-0374-3

In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-016-0374-3

Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-016-0374-3

Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-016-0374-3

Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-016-0374-3

MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-016-0374-3

Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-016-0374-3

Multi-institutional phase II study of selumetinib in patients with metastatic biliary cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-016-0374-3

Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-016-0374-3

Antitumor activity of targeted and cytotoxic agents in murine subcutaneous tumor models correlates with clinical response

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-016-0374-3

Preclinical disposition of GDC-0973 and prospective and retrospective analysis of human dose and efficacy predictions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-016-0374-3

Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-016-0374-3

Compliance with PET acquisition protocols for therapeutic monitoring of erlotinib therapy in an international trial for patients with non-small cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-016-0374-3

Mutation scanning using MUT-MAP, a high-throughput, microfluidic chip-based, multi-analyte panel

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-016-0374-3

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-016-0374-3

Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-016-0374-3

First-in-human, phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of RO5126766, a first-in-class dual MEK/RAF inhibitor in patients with solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-016-0374-3

Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-016-0374-3

Phase I and pharmacokinetic/pharmacodynamic study of RO5126766, a first-in-class dual Raf/MEK inhibitor, in Japanese patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-016-0374-3

Combination of vemurafenib and cobimetinib in patients with advanced BRAF(V600)-mutated melanoma: a phase 1b study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-016-0374-3

Combined vemurafenib and cobimetinib in BRAF-mutated melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-016-0374-3

Improved survival with MEK inhibition in BRAF-mutated melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-016-0374-3

Phase II trial of MEK inhibitor selumetinib (AZD6244, ARRY-142886) in patients with BRAFV600E/K-mutated melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-016-0374-3

Multicenter phase I trial of the mitogen-activated protein kinase 1/2 inhibitor BAY 86-9766 in patients with advanced cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-016-0374-3

Mutations of the BRAF gene in human cancer

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/27424159

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

A Phase II, open-label, randomised study to assess the efficacy and safety of the MEK1/2 inhibitor AZD6244 (ARRY-142886) versus capecitabine monotherapy in patients with colorectal cancer who have failed one or two prior chemotherapeutic regimens

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/27424159

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/27424159

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S10637-016-0374-3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27424159%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27424159%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

PubMed publication ID

27424159

1 reference